Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755889 | 0.80 | CYP19A1 (0.47) | ALDH1A1 | |
| SCHEMBL15423917 | 0.77 | ALDH1A1 (0.44) | ALDH1A1CTSBATMMAPTHPGD | |
| SCHEMBL15425042 | 0.73 | TACR1 (0.48) | ALDH1A1CTSBATMMAPTS1PR1 | |
| SCHEMBL4691605 | 0.69 | ALDH1A1 (0.60) | ALDH1A1HCAR2MAPK1L3MBTL1 | |
| SCHEMBL13259431 | 0.68 | TACR1 (0.52) | CTSBMAPTMAPK1 | |
| SCHEMBL10132648 | 0.66 | MAPT (0.39) | ALDH1A1ATMMAPTS1PR1MAPK1 | |
| SCHEMBL25013937 | 0.66 | SMN1; SMN2 (0.51) | ATM | |
| SCHEMBL29032094 | 0.65 | MIF (0.67) | MIFALDH1A1CTSBHCAR2MAPK1 | |
| SCHEMBL24049972 | 0.63 | ALDH1A1 (0.52) | MIFALDH1A1CTSBLTA4HLAP3 | |
| SCHEMBL11165126 | 0.63 | TDP1 (0.54) | ALDH1A1MAPTHPGDMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | MIF 2353/4885ALDH1A1 1144/4885CTSB 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.